Comparative Pharmacology
Head-to-head clinical analysis: AVSOLA versus IDACIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVSOLA versus IDACIO.
AVSOLA vs IDACIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tumor necrosis factor (TNF) alpha inhibitor; AVSOLA (infliximab-axxq) is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of TNF-alpha, thereby inhibiting binding of TNF-alpha to its receptors (TNFR1 and TNFR2) and reducing pro-inflammatory cytokine signaling.
IDACIO is a biosimilar to adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-alpha) and blocks its interaction with p55 and p75 cell surface TNF receptors. This neutralizes the pro-inflammatory effects of TNF-alpha, including cytokine release, adhesion molecule expression, and immune cell activation.
5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
40 mg subcutaneously once weekly. If methotrexate is not tolerated, monotherapy may be considered.
None Documented
None Documented
Terminal elimination half-life is approximately 14–18 days (range 10–39 days) in adults. Prolonged half-life supports dosing every 8 weeks; it is influenced by inflammation and disease severity.
Terminal elimination half-life is approximately 11-17 days (mean 14 days). Supports every-other-week dosing for maintenance of therapeutic concentrations.
Primarily cleared by the reticuloendothelial system via proteolytic degradation. Minimal renal excretion (less than 1% unchanged) and no significant biliary or fecal elimination.
Primarily degraded to amino acids via catabolic pathways; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination of active drug.
Category C
Category C
TNF-Alpha Inhibitor
TNF-Alpha Inhibitor